skip to main content
UK Health Security Agency

DLKP-I

DLKP-I

Catalogue No.

20022602

Cell Line Name

DLKP-I

Cell Line Description

DLKP-I is an intermediate morphology, clonal subpopulation of a poorly differentiated lung carcinoma (DLKP - ECACC accession number 20082601).

Intermediate morphology is best seen when compared to DLKP-SQ (ECACC accession number 20082604) and DLKP-M (ECACC accession number 20082603).

Characteristics

Tissue of Origin

Lung

DNA profile (STR Profile)

Amelogenin: X,X
CSF1PO: 11,12
D3S1358: 17
D5S818: 11
D7S820: 8,11
D8S1179: 13,14
D13S317: 12
D16S539: 10,12
D18S51: 13
FGA: 20
Penta D: 11
Penta E: 7,15
TH01: 9.3
TPOX: 8,11
vWA: 17

Karyotype

DLKP-I 36% hypertetraploid

Applications

DLKP-I has been used in drug resistance studies, and is anoikis sensitive.

Disease

Carcinoma

Culture Conditions

Subculture Routine

Upon resuscitation, count cells and seed at the higher end of the seeding density to establish culture.
Feed with fresh growth medium the following day.

Seed cells between 2-4x10e4 cells/cm² and feed twice a week.

Use Trypsin/EDTA to remove cells from the flask's surface.

Incubate at 8% CO2 at 37°C (as medium is a mixture of DMEM and Ham's F-12).

Culture Medium

DMEM:Hams F12 + 5% Foetal Bovine Serum (FBS) + 2mM L-Glutamine

Freeze in 5% DMSO ; 45% FBS; 50% growth medium.

Growth Mode

Adherent

Additional Info

Depositor

Martin Clynes National Institute for Cellular Biotechnology, Dublin City University. Originator: Geraldine Grant (1989): National Institute for Cellular Biotechnology (formerly National Cell and Tissue Culture Centre), Dublin City University

Country of Origin

Ireland

GMO Status

Not Applicable

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

McBride S, Meleady P, Baird A, Dinsdale D, Clynes M. Human lung carcinoma cell line DLKP contains 3 distinct subpopulations with different growth and attachment properties. Tumour Biol. 1998;19(2):88-103.

10.1159/000029979 PMID: 9486560

Bibliography

Keenan J, Joyce H, Aherne S, O'Dea S, Doolan P, Lynch V, Clynes M. Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung squamous carcinoma cell line. Exp Cell Res. 2012 Mar 10;318(5):593-602.

Law, E., Gilvarry, U., Lynch, V., Gregory, B., Grant, G., and Clynes, M., (1992). Cytogenetic comparison of two poorly differentiated human lung squamous cell carcinoma lines. Cancer Genet. Cytogenet. 59:111-118.

O'Driscoll L, Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets. 2006 Aug;6(5):365-84

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: DLKP-I (ECACC 20022602).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.

 

ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.